Gut microbiota composition is associated with polypharmacy in elderly hospitalized patients /692/700/1518 /692/308/575 article

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Ticinesi, Andrea ^a,b   Milani, Christian ^a   Lauretani, Fulvio ^a,b   Nouvenne, Antonio ^a,b   Mancabelli, Leonardo ^a   Lugli, Gabriele Andrea ^a   Turroni, Francesca ^a   Duranti, Sabrina ^a   Mangifesta, Marta ^a   Viappiani, Alice ^c   Ferrario, Chiara ^a   Maggio, Marcello ^a,b   Ventura, Marco ^a   Meschi, Tiziana ^a,b  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

^c Italy   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RNA 16S;

AGED; BIODIVERSITY; BIOLOGICAL VARIATION; COMORBIDITY; DRUG EFFECT; FEMALE; HOSPITALIZATION; HUMAN; INTESTINE FLORA; MALE; METAGENOME; METAGENOMICS; OUTCOME ASSESSMENT; PHENOTYPE; POLYPHARMACY; SURVIVAL ANALYSIS; SYMPTOM ASSESSMENT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIODIVERSITY; BIOLOGICAL VARIATION, POPULATION; COMORBIDITY; FEMALE; GASTROINTESTINAL MICROBIOME; HOSPITALIZATION; HUMANS; MALE; METAGENOME; METAGENOMICS; PATIENT OUTCOME ASSESSMENT; PHENOTYPE; POLYPHARMACY; RNA, RIBOSOMAL, 16S; SURVIVAL ANALYSIS; SYMPTOM ASSESSMENT;

EID: 85029304436     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-10734-y     Document Type: Article

References (52)

1. Vaiserman, A. M., Koliada, A. K. & Marotta, F. Gut microbiota: A player in aging and a target for anti-aging intervention. Ageing Res Rev. 35, 36-45 (2017).
2. Salazar, N., Valdes-Varela, L., Gonzalez, S., Gueimonde, M. & de los Reyes-Gavilan, C. G. Nutrition and the gut microbiome in the elderly. Gut Microbes. doi:10. 1080/19490976. 2016. 1256525 (2016).
3. Claesson, M. J. et al. Gut microbiota composition correlates with diet and health in the elderly. Nature. 488, 178-184 (2012).
4. O'Toole, P. W. & Jeffery, I. B. Gut microbiota and aging. Science. 350, 1214-1215 (2015).
5. Odamaki, T. et al. Age-related changes in gut microbiota composition from newborn to centenarian: A cross-sectional study. BMC Microbiol. 16, 90 (2016).
6. Biagi, E. et al. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. PLoS One. 5, e10667 (2010).
7. Biagi, E. et al. Gut microbiota and extreme longevity. Curr Biol. 26, 1480-1485 (2016).
8. Jeffery, I. B., Lynch, D. B. & O'Toole, P. W. Composition and temporal stability of gut microbiota in older persons. ISME J. 10, 170-182 (2016).
9. Milani, C. et al. The human gut microbiota and its interactive connections to diet. J Hum Nutr Diet. 29, 539-546 (2016).
10. Claesson, M. J. et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci USA. 108, 4586-4591 (2011).
11. Zhang, D. et al. Neutrophil ageing is regulated by the microbiome. Nature. 525, 528-532 (2015).
12. Sonnenburg, J. L. & Backhed, F. Diet-microbiota interactions as moderators of human metabolism. Nature. 535, 56-64 (2016).
13. Jackson, M. A. et al. Signatures of early frailty in the gut microbiota. Genome Med. 8, 8 (2016).
14. Mello, A. M., Paroni, G., Daragjati, J. & Pilotto, A. Gastrointestinal microbiota and their contribution to healthy aging. Dig Dis. 34, 194-201 (2016).
15. Milani, C. et al. Gut microbiota composition and Clostridium difficile infection in hospitalized elderly individuals: A metagenomic study. Sci Rep. 6, 25945 (2016).
16. Meschi, T. et al. A novel organizational model to face the challenge of multimorbid elderly patients in an internal medicine setting: A case study from Parma Hospital, Italy. Intern Emerg Med. 11, 667-676 (2016).
17. Lynch, S. V. & Pedersen, O. The human intestinal microbiome in health and disease. N Engl J Med. 375, 2369-2379 (2016).
18. Salvi, F. et al. A manual of guidelines to score the cumulative illness rating scale and its validation in acute hospitalized elderly patients. J Am Geriatr Soc. 56, 1926-1931 (2008).
19. Rockwood, K. et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 173, 489-495 (2005).
20. Milani, C. et al. Assessing the fecal microbiota: An optimized ion torrent 16S rRNA gene-based analysis protocol. PLoS One. 8, e68739 (2013).
21. Caporaso, J. G. et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 7, 335-336 (2010).
22. Edgar, R. C. Search and clustering orders of magnitude faster than BLAST. Bioinformatics. 26, 2460-2461 (2010).
23. Quast, C. et al. The SILVA ribosomial RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res. 41, D590-D596 (2013).
24. Prescott, H. C. et al. Hospitalization type and subsequent severe sepsis. Am J Respir Crit Care Med. 192, 581-588 (2015).
25. Zapata, H. J. & Quagliarello, V. J. The microbiota and microbiome in aging: potential implications in health and age-related diseases. J Am Geriatr Soc. 63, 776-781 (2015).
26. Zhernakova, A. et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science. 352(6285), 565-569 (2016).
27. Rogers, M. A. M. & Aronoff, D. M. The influence of non-steroidal anti-inflammatory drugs on the gut microbiome. Clin Microbiol Infect. 22, 178. e1-178. e9 (2016).
28. Imhann, F. et al. The influence of proton pump inhibitors and other commonly used medication on the gut microbiota. Gut Microbes. . doi:10. 1080/19490976. 2017. 1284732 (2017).
29. Gnjidic, D. et al. Polypharmacy cut-off and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 65, 989-995 (2012).
30. Jackson, M. A. et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 65, 749-756 (2016).
31. Imhann, F. et al. Proton pump inhibitors affect the gut microbiome. Gut. 65, 740-748 (2016).
32. Macedo, D. et al. Antidepressants, antimicrobials or both Gut microbiota dysbiosis in depression and possible implications of the antimicrobial effects of antidepressant drugs for antidepressant effectiveness. J Affect Dis. 208, 22-32 (2017).
33. Bahr, S. M. et al. Use of second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children. Transl Psychiatry. 5, e652 (2015).
34. Morgan, A. P. et al. The antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse. PLoS One. 9, e115225 (2014).
35. Freedberg, D. E. et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: A crossover trial. Gastroenterology. 149, 883-885 (2015).
36. Wallace, J. L. et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology. 141, 1314-1322 (2011).
37. Shin, N. R. et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut. 63, 727-735 (2014).
38. Forslund, K. et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 528, 262-266 (2015).
39. Weiss, G. A. & Hennet, T. Mechanisms and consequences of intestinal dysbiosis. Cell Mol Life Sci. 74, 2959-2977 (2017).
40. Maurice, C. F., Haiser, H. J. & Turnbaugh, P. J. Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell. 152, 39-50 (2013).
41. Nichols, R. G., Hume, N. E., Smith, P. B., Peters, J. M. & Patterson, A. D. Omics approaches to probe microbiota and drug metabolism interactions. Clin Res Toxicol. 29, 1987-1997 (2016).
42. Swanson, H. I. Drug metabolism by the host and gut microbiota: A partnership or rivalry Drug Metab Dispos. 43, 1499-1504 (2015).
43. Goni, E. & Franceschi, F. Helicobacter pylori and extragastric diseases. Helicobacter. 21, 45-48 (2016).
44. Estaki, M. et al. Cardiorespiratory fitness as a predictor of intestinal microbial diversity and distinct metagenomics functions. Microbiome. 4, 42 (2016).
45. Le Chatelier, E. et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 500, 541-546 (2013).
46. Nakata, T. et al. Inhibitory effects of laminaran and alginate on production of putrefactive compounds from soy protein by intestinal microbiota in vitro and in rats. Carbohydr Polym. 143, 61-69 (2016).
47. Paroni Sterbini, F. et al. Effects of proton pump inhibitors on the gastric mucosa-associated microbiota in dyspeptic patients. Appl Environ Microbiol. 82, 6633-6644 (2016).
48. Gorvitovskaia, A., Holmes, S. P. & Huse, S. M. Interpreting Prevotella and Bacteroides as biomarkers of diet and lifestyle. Microbiome. 4, 15 (2016).
49. Bajaj, J. S. et al. Gut microbiota alterations can predict hospitalizations in cirrhosis independent of diabetes mellitus. Sci Rep. 5, 18559 (2015).
50. Tsai, C. F. et al. Proton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in a population-based study. Gastroenterology. 152, 134-141 (2017).
51. Ticinesi, A. et al. Multimorbidity in elderly hospitalised patients and risk of Clostridium difficile infection: A retrospective study with the Cumulative Illness Rating Scale (CIRS). BMJ Open. 5, e009316 (2010).
52. Nouvenne, A. et al. Comorbidities and disease severity as risk factors for carbapenem-resistant Klebsiella pneumoniae colonization: report of an experience in an internal medicine unit. PLoS One. 9, e110001 (2014).